Resistance of carbapenemase-producing Klebsiella pneumoniae isolated from patients with orthopedic infection | CMAC

Resistance of carbapenemase-producing Klebsiella pneumoniae isolated from patients with orthopedic infection

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):47-52

​ Bozhkova S.A., Gordina E.M., Schneider O.V., Rukina A.N., Shabanova V.V.
10.36488/cmac.2020.1.47-52
Klebsiella pneumoniae resistance carbapenemase orthopedic infection
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):47-52

Objective.

To evaluate the resistance rate and production of carbapenemases in Klebsiella pneumoniae with phenotypic resistance to carbapenems isolated from patients with orthopedic infection.

Materials and Methods.

The materials for the study were tissue samples, aspirates and removed orthopedic devices of patients with orthopedic infection at the Vreden Russian Research Institute of Traumatology and Orthopedics, between 2017 and 2019. K. pneumoniae strains were identified in Microlatest by iEMS ReaderMF. These strains were tested for susceptibility to 15 antimicrobial agents by disk diffusion methods, as described by the EUCAST. The carbapenemase genes were investigated by RT-PCR.

Results.

Of 858 isolated cultures, 6.8% were resistant to carbapenems. Molecular genetic analysis showed that 43.1% of the cultures had blaNDM gene and 24.1% blaOXA-48. All isolates of K. pneumoniae were characterized by resistance to cefotaxime, moxifloxacin and ciprofloxacin. OXA-48-strains were MDR in 50.0% of cases, XDR in 42.9%, PDR in 7.1%. Strains with NDM-carbapenemases were XDR in 68.0% and PDR in 32.0% of cases. The most effective antibiotic was fosfomycin. Thus, 66.7% of NDM-isolates demonstrated sensitivity to fosfomycin. One isolate was PDR with both NDM and OXA-48.

Conclusions.

Over the period of three years, carbapenemase-producing K. pneumoniae were isolated in the orthopedic hospital. These isolates were not only resistant to carbapenems, but also to a number of other antimicrobial agents. Isolates differed in resistance phenotypes depending on the presence of carbapenemases group, while strains with gene blaNDM were more resistant than those with blaOXA-48.

Svetlana A. Bozhkova

National Medical Research Center of Traumatology and Orthopedics named after R.R. Vreden, Saint-Petersburg, Russia

Ekaterina M. Gordina

National Medical Research Center of Traumatology and Orthopedics named after R.R. Vreden, Saint-Petersburg, Russia

Schneider O.V.

National Medical Research Center of Traumatology and Orthopedics named after R.R. Vreden, Saint-Petersburg, Russia

Rukina A.N.

National Medical Research Center of Traumatology and Orthopedics named after R.R. Vreden, Saint-Petersburg, Russia

Shabanova V.V.

National Medical Research Center of Traumatology and Orthopedics named after R.R. Vreden, Saint-Petersburg, Russia

  • 1. Schwaber M.J., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;5(3):1028-1033. DOI: 10.1128/AAC.01020-07
  • 2. Enfield K. B., Huq N.N., Gosseling M. F., Low D.J., Hazen K.C., Toney D.M., et al. Control of simultaneous outbreaks of carbapenemase-producing Enterobacteriaceae and extensively drug-resistant Acinetobacter baumannii infection in an intensive care unit using interventions promoted in the Centers for Disease Control and Prevention 2012 carbapenemaseresistant Enterobacteriaceae. Infect Control Hosp Epidemiol. 2014;35(7):810-817. DOI: 10.1086/676857
  • 3. Li C., Renz N., Trumpuz А., Ojeda-Thies C. Twenty common errors in the diagnosis and treatment of periprosthetic joint infection. Int Orthop. 2020;44(1):3-14. DOI: 10.1007/s00264-01904426-7
  • 4. Kärrholm J., Lindahl H., Malchau H., Mohaddes M., Nemes S., Rogmark C., et al. National Joint Registry for England and Wales. 2011. The Swedish Hip Arthroplasty Register. Annual Report 2016, 2017.
  • 5. Tikhilov R.M., Shubnyakov I.I., Kovalenko A.N., Totoyev Z.A., Lyu Bo, Bilyk S.S. The structure of early revisions after hip replacement. Travmatologija i ortopedija Rossii. 2014;(2):513. Russian.
  • 6. Wang L., Di Luca М., Tkhilaishvili T., Trampuz А., Gonzalez Moreno М. Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa. Front Microbiol. 2019;10:2522. DOI: 10.3389/fmicb.2019.02522
  • 7. Bozhkova S.A., Kasimova A.R., Tikhilov R.M., Polyakova E.M., Rukina A.N., Shabanova V.V., et al. Adverse Trends in the Etiology of Orthopedic Infection: Results of 6-Year Monitoring of the Structure and Resistance of Leading Pathogens. Travmatologija i ortopedija Rossii. 2018;24(4):20-31. Russian. DOI: 10.21823/2311-2905-2018-24-4-20-31
  • 8. Anganova E.V., Vetokhina A.V., Raspopina L.A., Kichigina E.L., Savilov E.D. State of antibiotics resistance of Klebsiella pneumoniae. Mikrobiologija. 2017;5:70-77. Russian.
  • 9. Sukhorukova M.V., Edelstein M.V., Ivanchik N.V., Skleenova E.Y., Shajdullina E.R., Azizov I.S., et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015-2016”. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):147159. Russian. DOI: 10.36488/cmac.2019.2.147-159
  • 10. Polischouk A.G., Jakubovich E.I., Poluhina O.V., Osovskich V.V., Evtushenko V.I. Сarbapenemase-producing gram-negative bacteria in a specialized hospital of St. Petersburg. Infekcija i immunitet. 2017;7(2):181-192. Russian. DOI: 10.15789/2220-7619-2017-2-181-192
  • 11. Mussi M.A., Limansky A.S., Viale A.M. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother. 2005;49(4):1432-1440. DOI: 10.1128/AAC.49.4.1432-1440.2005
  • 12. Doumith M., Ellington M.J., Livermore D.M., Woodford N. Molecular mechanisms disrupting porin expression in ertapenemresistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother. 2009;63(4):659-667. DOI: 10.1093/jac/dkp029
  • 13. Gutkind G., Di Conza J., Power P., Radice M. β-lactamasemediated resistance: a biochemical, epidemiological and genetic overview. Curr Pharm Des. 2013;19(2):164-208. PMID: 22894615
  • 14. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. DOI: 10.1111/j.1469-0691.2011.03570.x
  • 15. Bush K., Jacoby G. A. Updated functional classification of betalactamases. Antimicrob Agents Chemother. 2010;54(3):969976. DOI: 10.1128/AAC.01009-09
  • 16. Ageevets V.A., Partina I.V., Lisitsina E.S., Batyrshin I.M., Popenko L.N., Shlyapnikov S.A., el al. Susceptibility of Gramnegative Carbapenemase-Producing Bacteria to Various Group Antibiotics. Antibiotiki i himioterapija. 2013;58 (3-4):10-13. Russian.
  • 17. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. DOI: 10.1177/2049936115621709
  • 18. Naas T., Cuzon G., Truong H. V., Nordmann P. Role of ISKpn7 and deletions in blaKPC gene expression. Antimicrob Agents Chemother. 2012;56(9):4753-4759. DOI: 10.1128/AAC.00334-12
  • 19. Walsh T.R. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010;36(Suppl. 3):8-14. DOI: 10.1016/S0924-8579(10)70004-2
  • 20. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151-1161. DOI: 10.1128/AAC.45.4.11511161.2001
  • 21. Poirel L., Heritier C., Tolun V., Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48(1):15-22. DOI: 10.1128/aac.48.1.15-22.2004
  • 22. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046-5054. DOI: 10.1128/AAC.00774-09
  • 23. Shabanova V.V., Krasnova M.V., Bozhkova S.A., Ageevets V.A., Lazareva I.V., Rukina A.N., et al. The first case of isolation of Klebsiella pneumoniae ST147, producing NDM-1 carbapenemase, in trauma and orthopedic hospital in Russia. Travmatologija i ortopedija Rossii. 2015;(2):90-98. Russian.
  • 24. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0-9.0, 2017-2019. Available at: www.eucast.org.
  • 25. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785-796. DOI: 10.1016/S14733099(13)70190-7
  • 26. Gordinskaya N.A., Brusnigina N.F., Alekseeva A.E., Solntzev L.A., Savochkina Yu.A., Sabirova E.V., et al. The molecular characteristics of antibiotic-resistant strains of Klebsiella pneumoniae isolated in traumatology hospitals. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(3):243246. Russian.
  • 27. Bozhkova S.A, Polyakova E.M., AfanasievA.V., Labutin D.V., Vaganov G.V., Yudin V.E. Potential for the Use of Fosfomycin in the Topical Treatment of Periprosthetic Joint Infection. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(2):104112. Russian.
  • 28. Tapalski D.V. Susceptibility to antibiotic combinations among nosocomial carbapenemase-producing Gram-negative bacteria isolated in Belarus. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;20(3):182-191. Russian. DOI: 10.36488//cmac.2018.3.182-191
Views
0 Abstract
0 PDF
0 Crossref citations
Shared